In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UCB SA

Division of UCB Group
www.ucb.be

Latest From UCB SA

Lower-Cost Competitors Hit Amgen's Blockbusters

Q1 revenue was roughly in line with expectations, but product sales were lower than consensus as multiple blockbusters faced generic competitors and biosimilars – a scenario the company prepared investors for earlier this year.

Sales & Earnings Biosimilars

Public Citizen Sues US FDA To Get Boxed Warning On Dopamine Agonists For Compulsive Behaviors

Consumer group's languishing petition seeks class-wide REMS on risk of impulse control adverse events, such pathological gambling, hypersexuality, compulsive shopping, and binge eating caused by dopamine agonists.

Drug Safety Post Market Regulation & Studies

As Amgen's Aimovig Momentum Continues, Challenges To Current Blockbusters Loom Large

Q1 Earnings Preview: While investors will look for updates on Aimovig and Evenity launches and a recently revealed legal battle with partner Novartis, Amgen's current blockbusters also are in the hotseat.

Sales & Earnings Companies

Amgen Launches Evenity For High-Risk Osteoporosis At $21,900 List Price

Amgen EVP Murdo Gordon highlighted the unmet need for women at high risk, including those with a prior fracture. At $1,825 per month or $21,900 for a one-year course in the US, he says Evenity's cost is much lower versus competing 18- and 24-month anabolic agents.

Launches Pricing Strategies
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register